Mylan Laboratories Limited

Belkins
Mylan India is a part of Mylan Inc. U.S one of the world’s leading generic and specialty pharmaceutical companies. In India we have strong manufacturing base with Active Pharmaceutical Ingredients, Oral Solid Dosage and Injectable units spread across the country. The company also has exceptional R&D facilities and fast growing commercial operations in India. Mylan India comprises of nearly 50% of Mylan Inc.’s total global workforce.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

news image

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More

RESEARCH

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS | December 07, 2020

news image

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More

BUSINESS INSIGHTS

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems | October 07, 2021

news image

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

news image

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

Glenmark Pharmaceuticals Inc | October 19, 2020

news image

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More

RESEARCH

IDBS | December 07, 2020

news image

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More

BUSINESS INSIGHTS

Veeva Systems | October 07, 2021

news image

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More

Acacia Pharma Group plc | October 12, 2020

news image

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More